Please Wait.....
Report
Nicotine Replacement Therapy Market By Product (Gums, Lozenges, Patches, Others), By Sales Channel (Online, Offline), By Location (Hospitals and Deaddiction centers, Home): Global Opportunity Analysis and Industry Forecast, 2021-2031
Market Report I 2022-10-01 I 290 Pages I Allied Market Research
The global nicotine replacement therapy market was valued at $2,659.0 million in 2021, and is projected to reach $5,955.95 million by 2031, registering a CAGR of 8.3% from 2022 to 2031.
Nicotine replacement therapy is a medically approved way to treat people with tobacco use disorder by taking nicotine by means other than tobacco. The nicotine replacement products such as nicotine gum and patches work by providing nicotine to the body to decrease the withdrawal symptoms experienced when smoking is stopped and as a substitute oral activity to reduce the urge to smoke.
The increase in prevalence of tobacco cancer owing to high cigarette smoking rate in urban cities drives the growth of the nicotine replacement therapy market. In addition, there is high tobacco chewing rate in rural area in both males and females, which further increases the risk of cancer. For instance, according to the report of American Cancer Society (ACS) published in October 2020, tobacco use remains the leading preventable cause of death in the U.S., accounting for about 1 in 5 deaths each year. From the same source, smoking causes about 20% of all cancers and about 30% of all cancer deaths in the U.S.
Furthermore, rise in awareness about cancer and increase in initiatives by respective governments to promote awareness about the risk associated with tobacco consumption contributes to the growth of the market. In addition, various non-government and non-profit organizations operate to promote awareness about hazardous effects of smoking, which further boosts the demand for nicotine replacement therapy.
The rise in demand for smoking cessation aids such as nicotine gums and patches owing to social media awareness campaigns and government awareness programs motivating people to quit smoking, provides ample opportunities for the market growth. Nicotine replacement therapy reduces the withdrawal symptoms and helps to control the drive to smoke tobacco.
Moreover, the increase in R&D activities for development of advanced nicotine replacement therapy, product approvals, and novel product launches by key players boost the market growth. The patient centric products development such as nicotine gums and lozenges propels the demand for nicotine replacement products. However, strict government regulations and ban of e cigarettes in many countries may hinder the growth of the market.
The nicotine replacement therapy market is segmented based on product, sales channel, location, and region. By product, the market is classified into gums, lozenges, patches, and others. Depending on sales channel, it is divided into online and offline. As per location, it is categorized into hospitals & deaddiction centers and home. The hospitals & deaddiction centers is further divided into male and female. The home segment is further bifurcated into male and female. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include Cipla Limited, Fertin Pharma Ltd., GlaxoSmithKline plc, Johnson & Johnson Inc., Lucy Goods, Inc., Pfizer Inc., PL Developments, Rubicon Research Pvt. Ltd., Sparsha Pharma International Pvt. Ltd., and Zydus Cadila.
Key Benefits For Stakeholders
-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the nicotine replacement therapy market analysis from 2021 to 2031 to identify the prevailing nicotine replacement therapy market opportunities.
-The market research is offered along with information related to key drivers, restraints, and opportunities.
-Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
-In-depth analysis of the nicotine replacement therapy market segmentation assists to determine the prevailing market opportunities.
-Major countries in each region are mapped according to their revenue contribution to the global market.
-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
-The report includes the analysis of the regional as well as global nicotine replacement therapy market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Product
- Gums
- Lozenges
- Patches
- Others
By Sales Channel
- Online
- Offline
By Location
- Hospitals and Deaddiction centers
- Gender
- Male
- Female
- Home
- Gender
- Male
- Female
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest Of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest Of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest Of LAMEA
- Key Market Players
- Cipla Ltd
- Fertin Pharma Limited
- GlaxoSmithKline plc
- Johnson & Johnson Inc
- Lucy Goods Inc
- Pfizer Inc
- PL Developments
- Rubicon Research Pvt Ltd
- Sparsha Pharma International Pvt. Ltd.
- Zydus Cadila
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Market dynamics
3.4.1.Drivers
3.4.2.Restraints
3.4.3.Opportunities
3.5.COVID-19 Impact Analysis on the market
CHAPTER 4: NICOTINE REPLACEMENT THERAPY MARKET, BY PRODUCT
4.1 Overview
4.1.1 Market size and forecast
4.2. Gums
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.3. Lozenges
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
4.4. Patches
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market share analysis by country
4.5. Others
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market share analysis by country
CHAPTER 5: NICOTINE REPLACEMENT THERAPY MARKET, BY SALES CHANNEL
5.1 Overview
5.1.1 Market size and forecast
5.2. Online
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3. Offline
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
CHAPTER 6: NICOTINE REPLACEMENT THERAPY MARKET, BY LOCATION
6.1 Overview
6.1.1 Market size and forecast
6.2. Hospitals and Deaddiction centers
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market share analysis by country
6.2.4 Hospitals and Deaddiction centers Nicotine Replacement Therapy Market by Gender
6.2.4.1 Male Market size and forecast, by region
6.2.4.2 Female Market size and forecast, by region
6.3. Home
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market share analysis by country
6.3.4 Home Nicotine Replacement Therapy Market by Gender
6.3.4.1 Male Market size and forecast, by region
6.3.4.2 Female Market size and forecast, by region
CHAPTER 7: NICOTINE REPLACEMENT THERAPY MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Product
7.2.3 North America Market size and forecast, by Sales Channel
7.2.4 North America Market size and forecast, by Location
7.2.4.1 North America Hospitals and Deaddiction centers Nicotine Replacement Therapy Market by Gender
7.2.4.2 North America Home Nicotine Replacement Therapy Market by Gender
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Key market trends, growth factors and opportunities
7.2.5.1.2 Market size and forecast, by Product
7.2.5.1.3 Market size and forecast, by Sales Channel
7.2.5.1.4 Market size and forecast, by Location
7.2.5.2 Canada
7.2.5.2.1 Key market trends, growth factors and opportunities
7.2.5.2.2 Market size and forecast, by Product
7.2.5.2.3 Market size and forecast, by Sales Channel
7.2.5.2.4 Market size and forecast, by Location
7.2.5.3 Mexico
7.2.5.3.1 Key market trends, growth factors and opportunities
7.2.5.3.2 Market size and forecast, by Product
7.2.5.3.3 Market size and forecast, by Sales Channel
7.2.5.3.4 Market size and forecast, by Location
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Product
7.3.3 Europe Market size and forecast, by Sales Channel
7.3.4 Europe Market size and forecast, by Location
7.3.4.1 Europe Hospitals and Deaddiction centers Nicotine Replacement Therapy Market by Gender
7.3.4.2 Europe Home Nicotine Replacement Therapy Market by Gender
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Key market trends, growth factors and opportunities
7.3.5.1.2 Market size and forecast, by Product
7.3.5.1.3 Market size and forecast, by Sales Channel
7.3.5.1.4 Market size and forecast, by Location
7.3.5.2 France
7.3.5.2.1 Key market trends, growth factors and opportunities
7.3.5.2.2 Market size and forecast, by Product
7.3.5.2.3 Market size and forecast, by Sales Channel
7.3.5.2.4 Market size and forecast, by Location
7.3.5.3 UK
7.3.5.3.1 Key market trends, growth factors and opportunities
7.3.5.3.2 Market size and forecast, by Product
7.3.5.3.3 Market size and forecast, by Sales Channel
7.3.5.3.4 Market size and forecast, by Location
7.3.5.4 Italy
7.3.5.4.1 Key market trends, growth factors and opportunities
7.3.5.4.2 Market size and forecast, by Product
7.3.5.4.3 Market size and forecast, by Sales Channel
7.3.5.4.4 Market size and forecast, by Location
7.3.5.5 Spain
7.3.5.5.1 Key market trends, growth factors and opportunities
7.3.5.5.2 Market size and forecast, by Product
7.3.5.5.3 Market size and forecast, by Sales Channel
7.3.5.5.4 Market size and forecast, by Location
7.3.5.6 Rest of Europe
7.3.5.6.1 Key market trends, growth factors and opportunities
7.3.5.6.2 Market size and forecast, by Product
7.3.5.6.3 Market size and forecast, by Sales Channel
7.3.5.6.4 Market size and forecast, by Location
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Product
7.4.3 Asia-Pacific Market size and forecast, by Sales Channel
7.4.4 Asia-Pacific Market size and forecast, by Location
7.4.4.1 Asia-Pacific Hospitals and Deaddiction centers Nicotine Replacement Therapy Market by Gender
7.4.4.2 Asia-Pacific Home Nicotine Replacement Therapy Market by Gender
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Key market trends, growth factors and opportunities
7.4.5.1.2 Market size and forecast, by Product
7.4.5.1.3 Market size and forecast, by Sales Channel
7.4.5.1.4 Market size and forecast, by Location
7.4.5.2 China
7.4.5.2.1 Key market trends, growth factors and opportunities
7.4.5.2.2 Market size and forecast, by Product
7.4.5.2.3 Market size and forecast, by Sales Channel
7.4.5.2.4 Market size and forecast, by Location
7.4.5.3 Australia
7.4.5.3.1 Key market trends, growth factors and opportunities
7.4.5.3.2 Market size and forecast, by Product
7.4.5.3.3 Market size and forecast, by Sales Channel
7.4.5.3.4 Market size and forecast, by Location
7.4.5.4 India
7.4.5.4.1 Key market trends, growth factors and opportunities
7.4.5.4.2 Market size and forecast, by Product
7.4.5.4.3 Market size and forecast, by Sales Channel
7.4.5.4.4 Market size and forecast, by Location
7.4.5.5 South Korea
7.4.5.5.1 Key market trends, growth factors and opportunities
7.4.5.5.2 Market size and forecast, by Product
7.4.5.5.3 Market size and forecast, by Sales Channel
7.4.5.5.4 Market size and forecast, by Location
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Key market trends, growth factors and opportunities
7.4.5.6.2 Market size and forecast, by Product
7.4.5.6.3 Market size and forecast, by Sales Channel
7.4.5.6.4 Market size and forecast, by Location
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Product
7.5.3 LAMEA Market size and forecast, by Sales Channel
7.5.4 LAMEA Market size and forecast, by Location
7.5.4.1 LAMEA Hospitals and Deaddiction centers Nicotine Replacement Therapy Market by Gender
7.5.4.2 LAMEA Home Nicotine Replacement Therapy Market by Gender
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Key market trends, growth factors and opportunities
7.5.5.1.2 Market size and forecast, by Product
7.5.5.1.3 Market size and forecast, by Sales Channel
7.5.5.1.4 Market size and forecast, by Location
7.5.5.2 Saudi Arabia
7.5.5.2.1 Key market trends, growth factors and opportunities
7.5.5.2.2 Market size and forecast, by Product
7.5.5.2.3 Market size and forecast, by Sales Channel
7.5.5.2.4 Market size and forecast, by Location
7.5.5.3 South Africa
7.5.5.3.1 Key market trends, growth factors and opportunities
7.5.5.3.2 Market size and forecast, by Product
7.5.5.3.3 Market size and forecast, by Sales Channel
7.5.5.3.4 Market size and forecast, by Location
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Key market trends, growth factors and opportunities
7.5.5.4.2 Market size and forecast, by Product
7.5.5.4.3 Market size and forecast, by Sales Channel
7.5.5.4.4 Market size and forecast, by Location
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021
CHAPTER 9: COMPANY PROFILES
9.1 Cipla Ltd
9.1.1 Company overview
9.1.2 Key Executives
9.1.3 Company snapshot
9.1.4 Operating business segments
9.1.5 Product portfolio
9.1.6 Business performance
9.1.7 Key strategic moves and developments
9.2 Fertin Pharma Limited
9.2.1 Company overview
9.2.2 Key Executives
9.2.3 Company snapshot
9.2.4 Operating business segments
9.2.5 Product portfolio
9.2.6 Business performance
9.2.7 Key strategic moves and developments
9.3 GlaxoSmithKline plc
9.3.1 Company overview
9.3.2 Key Executives
9.3.3 Company snapshot
9.3.4 Operating business segments
9.3.5 Product portfolio
9.3.6 Business performance
9.3.7 Key strategic moves and developments
9.4 Johnson & Johnson Inc
9.4.1 Company overview
9.4.2 Key Executives
9.4.3 Company snapshot
9.4.4 Operating business segments
9.4.5 Product portfolio
9.4.6 Business performance
9.4.7 Key strategic moves and developments
9.5 Lucy Goods Inc
9.5.1 Company overview
9.5.2 Key Executives
9.5.3 Company snapshot
9.5.4 Operating business segments
9.5.5 Product portfolio
9.5.6 Business performance
9.5.7 Key strategic moves and developments
9.6 Pfizer Inc
9.6.1 Company overview
9.6.2 Key Executives
9.6.3 Company snapshot
9.6.4 Operating business segments
9.6.5 Product portfolio
9.6.6 Business performance
9.6.7 Key strategic moves and developments
9.7 PL Developments
9.7.1 Company overview
9.7.2 Key Executives
9.7.3 Company snapshot
9.7.4 Operating business segments
9.7.5 Product portfolio
9.7.6 Business performance
9.7.7 Key strategic moves and developments
9.8 Rubicon Research Pvt Ltd
9.8.1 Company overview
9.8.2 Key Executives
9.8.3 Company snapshot
9.8.4 Operating business segments
9.8.5 Product portfolio
9.8.6 Business performance
9.8.7 Key strategic moves and developments
9.9 Sparsha Pharma International Pvt. Ltd.
9.9.1 Company overview
9.9.2 Key Executives
9.9.3 Company snapshot
9.9.4 Operating business segments
9.9.5 Product portfolio
9.9.6 Business performance
9.9.7 Key strategic moves and developments
9.10 Zydus Cadila
9.10.1 Company overview
9.10.2 Key Executives
9.10.3 Company snapshot
9.10.4 Operating business segments
9.10.5 Product portfolio
9.10.6 Business performance
9.10.7 Key strategic moves and developments
LIST OF TABLES
TABLE 1. GLOBAL NICOTINE REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
TABLE 2. NICOTINE REPLACEMENT THERAPY MARKET FOR GUMS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 3. NICOTINE REPLACEMENT THERAPY MARKET FOR LOZENGES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 4. NICOTINE REPLACEMENT THERAPY MARKET FOR PATCHES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 5. NICOTINE REPLACEMENT THERAPY MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 6. GLOBAL NICOTINE REPLACEMENT THERAPY MARKET, BY SALES CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 7. NICOTINE REPLACEMENT THERAPY MARKET FOR ONLINE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 8. NICOTINE REPLACEMENT THERAPY MARKET FOR OFFLINE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 9. GLOBAL NICOTINE REPLACEMENT THERAPY MARKET, BY LOCATION, 2021-2031 (REVENUE, $MILLION)
TABLE 10. NICOTINE REPLACEMENT THERAPY MARKET FOR HOSPITALS AND DEADDICTION CENTERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 11. GLOBAL HOSPITALS AND DEADDICTION CENTERS NICOTINE REPLACEMENT THERAPY MARKET, BY GENDER, 2021-2031 (REVENUE, $MILLION)
TABLE 12. NICOTINE REPLACEMENT THERAPY MARKET FOR MALE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 13. NICOTINE REPLACEMENT THERAPY MARKET FOR FEMALE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 14. NICOTINE REPLACEMENT THERAPY MARKET FOR HOME, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 15. GLOBAL HOME NICOTINE REPLACEMENT THERAPY MARKET, BY GENDER, 2021-2031 (REVENUE, $MILLION)
TABLE 16. NICOTINE REPLACEMENT THERAPY MARKET FOR MALE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 17. NICOTINE REPLACEMENT THERAPY MARKET FOR FEMALE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 18. NICOTINE REPLACEMENT THERAPY MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 19. NORTH AMERICA NICOTINE REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
TABLE 20. NORTH AMERICA NICOTINE REPLACEMENT THERAPY MARKET, BY SALES CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 21. NORTH AMERICA NICOTINE REPLACEMENT THERAPY MARKET, BY LOCATION, 2021-2031 (REVENUE, $MILLION)
TABLE 22. NORTH AMERICA HOSPITALS AND DEADDICTION CENTERS NICOTINE REPLACEMENT THERAPY MARKET, BY GENDER, 2021-2031 (REVENUE, $MILLION)
TABLE 23. NORTH AMERICA HOME NICOTINE REPLACEMENT THERAPY MARKET, BY GENDER, 2021-2031 (REVENUE, $MILLION)
TABLE 24. NORTH AMERICA NICOTINE REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 25. U.S. NICOTINE REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
TABLE 26. U.S. NICOTINE REPLACEMENT THERAPY MARKET, BY SALES CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 27. U.S. NICOTINE REPLACEMENT THERAPY MARKET, BY LOCATION, 2021-2031 (REVENUE, $MILLION)
TABLE 28. CANADA NICOTINE REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
TABLE 29. CANADA NICOTINE REPLACEMENT THERAPY MARKET, BY SALES CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 30. CANADA NICOTINE REPLACEMENT THERAPY MARKET, BY LOCATION, 2021-2031 (REVENUE, $MILLION)
TABLE 31. MEXICO NICOTINE REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
TABLE 32. MEXICO NICOTINE REPLACEMENT THERAPY MARKET, BY SALES CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 33. MEXICO NICOTINE REPLACEMENT THERAPY MARKET, BY LOCATION, 2021-2031 (REVENUE, $MILLION)
TABLE 34. EUROPE NICOTINE REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
TABLE 35. EUROPE NICOTINE REPLACEMENT THERAPY MARKET, BY SALES CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 36. EUROPE NICOTINE REPLACEMENT THERAPY MARKET, BY LOCATION, 2021-2031 (REVENUE, $MILLION)
TABLE 37. EUROPE HOSPITALS AND DEADDICTION CENTERS NICOTINE REPLACEMENT THERAPY MARKET, BY GENDER, 2021-2031 (REVENUE, $MILLION)
TABLE 38. EUROPE HOME NICOTINE REPLACEMENT THERAPY MARKET, BY GENDER, 2021-2031 (REVENUE, $MILLION)
TABLE 39. EUROPE NICOTINE REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 40. GERMANY NICOTINE REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
TABLE 41. GERMANY NICOTINE REPLACEMENT THERAPY MARKET, BY SALES CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 42. GERMANY NICOTINE REPLACEMENT THERAPY MARKET, BY LOCATION, 2021-2031 (REVENUE, $MILLION)
TABLE 43. FRANCE NICOTINE REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
TABLE 44. FRANCE NICOTINE REPLACEMENT THERAPY MARKET, BY SALES CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 45. FRANCE NICOTINE REPLACEMENT THERAPY MARKET, BY LOCATION, 2021-2031 (REVENUE, $MILLION)
TABLE 46. UK NICOTINE REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
TABLE 47. UK NICOTINE REPLACEMENT THERAPY MARKET, BY SALES CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 48. UK NICOTINE REPLACEMENT THERAPY MARKET, BY LOCATION, 2021-2031 (REVENUE, $MILLION)
TABLE 49. ITALY NICOTINE REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
TABLE 50. ITALY NICOTINE REPLACEMENT THERAPY MARKET, BY SALES CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 51. ITALY NICOTINE REPLACEMENT THERAPY MARKET, BY LOCATION, 2021-2031 (REVENUE, $MILLION)
TABLE 52. SPAIN NICOTINE REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
TABLE 53. SPAIN NICOTINE REPLACEMENT THERAPY MARKET, BY SALES CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 54. SPAIN NICOTINE REPLACEMENT THERAPY MARKET, BY LOCATION, 2021-2031 (REVENUE, $MILLION)
TABLE 55. REST OF EUROPE NICOTINE REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
TABLE 56. REST OF EUROPE NICOTINE REPLACEMENT THERAPY MARKET, BY SALES CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 57. REST OF EUROPE NICOTINE REPLACEMENT THERAPY MARKET, BY LOCATION, 2021-2031 (REVENUE, $MILLION)
TABLE 58. ASIA-PACIFIC NICOTINE REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
TABLE 59. ASIA-PACIFIC NICOTINE REPLACEMENT THERAPY MARKET, BY SALES CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 60. ASIA-PACIFIC NICOTINE REPLACEMENT THERAPY MARKET, BY LOCATION, 2021-2031 (REVENUE, $MILLION)
TABLE 61. ASIA-PACIFIC HOSPITALS AND DEADDICTION CENTERS NICOTINE REPLACEMENT THERAPY MARKET, BY GENDER, 2021-2031 (REVENUE, $MILLION)
TABLE 62. ASIA-PACIFIC HOME NICOTINE REPLACEMENT THERAPY MARKET, BY GENDER, 2021-2031 (REVENUE, $MILLION)
TABLE 63. ASIA-PACIFIC NICOTINE REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 64. JAPAN NICOTINE REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
TABLE 65. JAPAN NICOTINE REPLACEMENT THERAPY MARKET, BY SALES CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 66. JAPAN NICOTINE REPLACEMENT THERAPY MARKET, BY LOCATION, 2021-2031 (REVENUE, $MILLION)
TABLE 67. CHINA NICOTINE REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
TABLE 68. CHINA NICOTINE REPLACEMENT THERAPY MARKET, BY SALES CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 69. CHINA NICOTINE REPLACEMENT THERAPY MARKET, BY LOCATION, 2021-2031 (REVENUE, $MILLION)
TABLE 70. AUSTRALIA NICOTINE REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
TABLE 71. AUSTRALIA NICOTINE REPLACEMENT THERAPY MARKET, BY SALES CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 72. AUSTRALIA NICOTINE REPLACEMENT THERAPY MARKET, BY LOCATION, 2021-2031 (REVENUE, $MILLION)
TABLE 73. INDIA NICOTINE REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
TABLE 74. INDIA NICOTINE REPLACEMENT THERAPY MARKET, BY SALES CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 75. INDIA NICOTINE REPLACEMENT THERAPY MARKET, BY LOCATION, 2021-2031 (REVENUE, $MILLION)
TABLE 76. SOUTH KOREA NICOTINE REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
TABLE 77. SOUTH KOREA NICOTINE REPLACEMENT THERAPY MARKET, BY SALES CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 78. SOUTH KOREA NICOTINE REPLACEMENT THERAPY MARKET, BY LOCATION, 2021-2031 (REVENUE, $MILLION)
TABLE 79. REST OF ASIA-PACIFIC NICOTINE REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
TABLE 80. REST OF ASIA-PACIFIC NICOTINE REPLACEMENT THERAPY MARKET, BY SALES CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 81. REST OF ASIA-PACIFIC NICOTINE REPLACEMENT THERAPY MARKET, BY LOCATION, 2021-2031 (REVENUE, $MILLION)
TABLE 82. LAMEA NICOTINE REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
TABLE 83. LAMEA NICOTINE REPLACEMENT THERAPY MARKET, BY SALES CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 84. LAMEA NICOTINE REPLACEMENT THERAPY MARKET, BY LOCATION, 2021-2031 (REVENUE, $MILLION)
TABLE 85. LAMEA HOSPITALS AND DEADDICTION CENTERS NICOTINE REPLACEMENT THERAPY MARKET, BY GENDER, 2021-2031 (REVENUE, $MILLION)
TABLE 86. LAMEA HOME NICOTINE REPLACEMENT THERAPY MARKET, BY GENDER, 2021-2031 (REVENUE, $MILLION)
TABLE 87. LAMEA NICOTINE REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 88. BRAZIL NICOTINE REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
TABLE 89. BRAZIL NICOTINE REPLACEMENT THERAPY MARKET, BY SALES CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 90. BRAZIL NICOTINE REPLACEMENT THERAPY MARKET, BY LOCATION, 2021-2031 (REVENUE, $MILLION)
TABLE 91. SAUDI ARABIA NICOTINE REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
TABLE 92. SAUDI ARABIA NICOTINE REPLACEMENT THERAPY MARKET, BY SALES CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 93. SAUDI ARABIA NICOTINE REPLACEMENT THERAPY MARKET, BY LOCATION, 2021-2031 (REVENUE, $MILLION)
TABLE 94. SOUTH AFRICA NICOTINE REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
TABLE 95. SOUTH AFRICA NICOTINE REPLACEMENT THERAPY MARKET, BY SALES CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 96. SOUTH AFRICA NICOTINE REPLACEMENT THERAPY MARKET, BY LOCATION, 2021-2031 (REVENUE, $MILLION)
TABLE 97. REST OF LAMEA NICOTINE REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
TABLE 98. REST OF LAMEA NICOTINE REPLACEMENT THERAPY MARKET, BY SALES CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 99. REST OF LAMEA NICOTINE REPLACEMENT THERAPY MARKET, BY LOCATION, 2021-2031 (REVENUE, $MILLION)
TABLE 100. CIPLA LTD: KEY EXECUTIVES
TABLE 101. CIPLA LTD: COMPANY SNAPSHOT
TABLE 102. CIPLA LTD: OPERATING SEGMENTS
TABLE 103. CIPLA LTD: PRODUCT PORTFOLIO
TABLE 104. CIPLA LTD: NET SALES
TABLE 105. CIPLA LTD: KEY STRATERGIES
TABLE 106. FERTIN PHARMA LIMITED: KEY EXECUTIVES
TABLE 107. FERTIN PHARMA LIMITED: COMPANY SNAPSHOT
TABLE 108. FERTIN PHARMA LIMITED: OPERATING SEGMENTS
TABLE 109. FERTIN PHARMA LIMITED: PRODUCT PORTFOLIO
TABLE 110. FERTIN PHARMA LIMITED: NET SALES
TABLE 111. FERTIN PHARMA LIMITED: KEY STRATERGIES
TABLE 112. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
TABLE 113. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 114. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 115. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 116. GLAXOSMITHKLINE PLC: NET SALES
TABLE 117. GLAXOSMITHKLINE PLC: KEY STRATERGIES
TABLE 118. JOHNSON & JOHNSON INC: KEY EXECUTIVES
TABLE 119. JOHNSON & JOHNSON INC: COMPANY SNAPSHOT
TABLE 120. JOHNSON & JOHNSON INC: OPERATING SEGMENTS
TABLE 121. JOHNSON & JOHNSON INC: PRODUCT PORTFOLIO
TABLE 122. JOHNSON & JOHNSON INC: NET SALES
TABLE 123. JOHNSON & JOHNSON INC: KEY STRATERGIES
TABLE 124. LUCY GOODS INC: KEY EXECUTIVES
TABLE 125. LUCY GOODS INC: COMPANY SNAPSHOT
TABLE 126. LUCY GOODS INC: OPERATING SEGMENTS
TABLE 127. LUCY GOODS INC: PRODUCT PORTFOLIO
TABLE 128. LUCY GOODS INC: NET SALES
TABLE 129. LUCY GOODS INC: KEY STRATERGIES
TABLE 130. PFIZER INC: KEY EXECUTIVES
TABLE 131. PFIZER INC: COMPANY SNAPSHOT
TABLE 132. PFIZER INC: OPERATING SEGMENTS
TABLE 133. PFIZER INC: PRODUCT PORTFOLIO
TABLE 134. PFIZER INC: NET SALES
TABLE 135. PFIZER INC: KEY STRATERGIES
TABLE 136. PL DEVELOPMENTS: KEY EXECUTIVES
TABLE 137. PL DEVELOPMENTS: COMPANY SNAPSHOT
TABLE 138. PL DEVELOPMENTS: OPERATING SEGMENTS
TABLE 139. PL DEVELOPMENTS: PRODUCT PORTFOLIO
TABLE 140. PL DEVELOPMENTS: NET SALES
TABLE 141. PL DEVELOPMENTS: KEY STRATERGIES
TABLE 142. RUBICON RESEARCH PVT LTD: KEY EXECUTIVES
TABLE 143. RUBICON RESEARCH PVT LTD: COMPANY SNAPSHOT
TABLE 144. RUBICON RESEARCH PVT LTD: OPERATING SEGMENTS
TABLE 145. RUBICON RESEARCH PVT LTD: PRODUCT PORTFOLIO
TABLE 146. RUBICON RESEARCH PVT LTD: NET SALES
TABLE 147. RUBICON RESEARCH PVT LTD: KEY STRATERGIES
TABLE 148. SPARSHA PHARMA INTERNATIONAL PVT. LTD.: KEY EXECUTIVES
TABLE 149. SPARSHA PHARMA INTERNATIONAL PVT. LTD.: COMPANY SNAPSHOT
TABLE 150. SPARSHA PHARMA INTERNATIONAL PVT. LTD.: OPERATING SEGMENTS
TABLE 151. SPARSHA PHARMA INTERNATIONAL PVT. LTD.: PRODUCT PORTFOLIO
TABLE 152. SPARSHA PHARMA INTERNATIONAL PVT. LTD.: NET SALES
TABLE 153. SPARSHA PHARMA INTERNATIONAL PVT. LTD.: KEY STRATERGIES
TABLE 154. ZYDUS CADILA: KEY EXECUTIVES
TABLE 155. ZYDUS CADILA: COMPANY SNAPSHOT
TABLE 156. ZYDUS CADILA: OPERATING SEGMENTS
TABLE 157. ZYDUS CADILA: PRODUCT PORTFOLIO
TABLE 158. ZYDUS CADILA: NET SALES
TABLE 159. ZYDUS CADILA: KEY STRATERGIES
LIST OF FIGURES
FIGURE 1. SEGMENTATION OF NICOTINE REPLACEMENT THERAPY MARKET,2021-2031
FIGURE 2. NICOTINE REPLACEMENT THERAPY MARKET,2021-2031
FIGURE 3. TOP INVESTMENT POCKETS, BY REGION
FIGURE 4. PORTER FIVE-1
FIGURE 5. PORTER FIVE-2
FIGURE 6. PORTER FIVE-3
FIGURE 7. PORTER FIVE-4
FIGURE 8. PORTER FIVE-5
FIGURE 9. NICOTINE REPLACEMENT THERAPY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 10. NICOTINE REPLACEMENT THERAPY MARKET,BY PRODUCT,2021(%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF GUMS NICOTINE REPLACEMENT THERAPY MARKET, 2021 AND 2031(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF LOZENGES NICOTINE REPLACEMENT THERAPY MARKET, 2021 AND 2031(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PATCHES NICOTINE REPLACEMENT THERAPY MARKET, 2021 AND 2031(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF OTHERS NICOTINE REPLACEMENT THERAPY MARKET, 2021 AND 2031(%)
FIGURE 15. NICOTINE REPLACEMENT THERAPY MARKET,BY SALES CHANNEL,2021(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ONLINE NICOTINE REPLACEMENT THERAPY MARKET, 2021 AND 2031(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF OFFLINE NICOTINE REPLACEMENT THERAPY MARKET, 2021 AND 2031(%)
FIGURE 18. NICOTINE REPLACEMENT THERAPY MARKET,BY LOCATION,2021(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF HOSPITALS AND DEADDICTION CENTERS NICOTINE REPLACEMENT THERAPY MARKET, 2021 AND 2031(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF HOME NICOTINE REPLACEMENT THERAPY MARKET, 2021 AND 2031(%)
FIGURE 21. NICOTINE REPLACEMENT THERAPY MARKET BY REGION,2021
FIGURE 22. U.S. NICOTINE REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
FIGURE 23. CANADA NICOTINE REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
FIGURE 24. MEXICO NICOTINE REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
FIGURE 25. GERMANY NICOTINE REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
FIGURE 26. FRANCE NICOTINE REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
FIGURE 27. UK NICOTINE REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
FIGURE 28. ITALY NICOTINE REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
FIGURE 29. SPAIN NICOTINE REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
FIGURE 30. REST OF EUROPE NICOTINE REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
FIGURE 31. JAPAN NICOTINE REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
FIGURE 32. CHINA NICOTINE REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
FIGURE 33. AUSTRALIA NICOTINE REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
FIGURE 34. INDIA NICOTINE REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
FIGURE 35. SOUTH KOREA NICOTINE REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
FIGURE 36. REST OF ASIA-PACIFIC NICOTINE REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
FIGURE 37. BRAZIL NICOTINE REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
FIGURE 38. SAUDI ARABIA NICOTINE REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
FIGURE 39. SOUTH AFRICA NICOTINE REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
FIGURE 40. REST OF LAMEA NICOTINE REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 44. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 45. COMPETITIVE DASHBOARD
FIGURE 46. COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 47. TOP PLAYER POSITIONING, 2021
FIGURE 48. CIPLA LTD.: NET SALES ($MILLION)
FIGURE 49. FERTIN PHARMA LIMITED.: NET SALES ($MILLION)
FIGURE 50. GLAXOSMITHKLINE PLC.: NET SALES ($MILLION)
FIGURE 51. JOHNSON & JOHNSON INC.: NET SALES ($MILLION)
FIGURE 52. LUCY GOODS INC.: NET SALES ($MILLION)
FIGURE 53. PFIZER INC.: NET SALES ($MILLION)
FIGURE 54. PL DEVELOPMENTS.: NET SALES ($MILLION)
FIGURE 55. RUBICON RESEARCH PVT LTD.: NET SALES ($MILLION)
FIGURE 56. SPARSHA PHARMA INTERNATIONAL PVT. LTD..: NET SALES ($MILLION)
FIGURE 57. ZYDUS CADILA.: NET SALES ($MILLION)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security